Key facts
- This page summarizes Clay Thorp's Form 4 filing for Clearside Biomedical, Inc. (CLSD).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 24 Feb 2025, 17:52.
Clay Thorp - 24 Feb 2025 Form 4 Insider Report for Clearside Biomedical, Inc. (CLSD)
- Reporting relationship
- Director
- Issuer ticker
- CLSD
- Reported as of
- 24 Feb 2025
- Net transaction value
- +$13,800
- SEC form
- 4
- Accepted by SEC
- 24 Feb 2025, 17:52:59 UTC
- Prior SEC filing
- 21 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Ballantyne, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Clay Thorp filed Form 4 for Clearside Biomedical, Inc. (CLSD) on 24 Feb 2025.
Change
- Previous filing in this sequence was filed on 21 Jun 2024.
- Current net transaction value: +$13,800.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CLSD
transaction
Common Stock
Purchase
- Transaction value
- $13,800
- Shares
- +15,000
- Change %
- +9.3%
- Price
- $0.9200
- Shares after
- 176,141
- Date
- 24 Feb 2025
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.90 to $0.9321 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Footnote F2
Includes an aggregate of 120,619 shares received as a pro rata distribution from Hatteras Venture Advisors III, LLC, Hatteras Venture Advisors IV SBIC, LLC, Hatteras Venture Advisors IV, LLC and Hatteras NC Fund, LP (the "Hatteras Entities"). In prior reports, the reporting person reported indirect beneficial ownership of 3,545,040 shares of the Issuer's common stock held by the Hatteras Entities.